Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza vaccine GSK1562902A Formulation 1 · 1 trial · 1 indication
Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Turkey/Turkey/01/2005 antigen. The A/Turkey/Turkey/01/2005 (A/TURK) vaccine strain was administered to groups receiving the adjuvanted Influenza vaccine GSK1562902A. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.
Any = occurrence of the symptom regardless of intensity grade. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.
| Arm | Type | Description |
|---|---|---|
| GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group | EXPERIMENTAL | Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region. |
| GSK1562902A Formulation 1 - Havrix / Havrix Jr Group | EXPERIMENTAL | Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region. |
| GSK1562902A Formulation 2 - Havrix / Havrix Jr Group | ACTIVE_COMPARATOR | Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region. |
| Havrix / Havrix Jr Group | ACTIVE_COMPARATOR | Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region. |
| Name | Type | Description |
|---|---|---|
| Influenza vaccine GSK1562902A Formulation 1 | BIOLOGICAL | Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group |
| Influenza vaccine GSK1562902A Formulation 2 | BIOLOGICAL | Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group |
| Havrix™ | BIOLOGICAL | Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group |
| Havrix™ Junior | BIOLOGICAL | Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group |
Inclusion Criteria: All subjects must satisfy ALL the following criteria at study entry: * Subjects for whom the investigator believes that the parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] can and will comply with the requirements of the protocol . * A male or female child 3 to 17 yea...
Influenza vaccine GSK1562902A Formulation 1 is an investigational vaccine being developed for the prevention of influenza. It is currently in Phase 3 clinical development and is intended for use in children, as the completed trial evaluated a prime-boost schedule in pediatric participants.
Influenza vaccine GSK1562902A Formulation 1 is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity.
Influenza vaccine GSK1562902A Formulation 1 is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the vaccine remains under clinical investigation.
Influenza vaccine GSK1562902A Formulation 1 has been studied in one completed Phase 3 clinical trial, NCT01379937. This trial evaluated the safety and immunogenicity of a prime-boost schedule of the vaccine in children aged 3 years and older in the Philippines, enrolling 520 participants.
Influenza vaccine GSK1562902A Formulation 1 is a specific investigational vaccine formulation developed by GSK. It is not known to be the same as other marketed influenza vaccines, as it is still in clinical development and has not been approved for use.